A recent report from the Massachusetts Health Policy Commission used publicly available drug pricing data in an attempt to identify proxies to highlight the differences between what health plan sponsors reimburse their pharmacy benefit managers (PBM) for a prescription versus
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
©2024 PCMA. All Rights Reserved.
